There's nothing cavalier about first and foremost recognising that competition is to be expected, and the market is more than large enough to make the fortunes of more than one pharmaceutical company. I also did not express that IHL's candidate would 'just be preferred': I was very specific in noting in what situations it would likely be preferred. But hey... if you want to ignore the nuance of what I'm saying, I can't prevent you.
